title: [The benefits and risks of hormonal replacement therapy--an update].
abstract: Hormonal replacement therapy (HRT) with estrogens and gestagens has been used for more than 40 years in the treatment of menopausal complaints and can be considered an effective treatment for vaso-vegetative symptoms and urogenital atrophy. During the past few years many women and doctors have revised their opinions of HRT. The reasons for this change of view are mainly three large international studies: the Heart and Estrogen/Progestin Study, the Women's Health Initiative Study and the One Million Women Study. In this review we summarize the data from the most important studies and point out the actual status of the controversial discussion on the benefits and risks of HRT.
authors.affiliation: Klinik fur Gynakologie und Geburtshilfe, Universitatsklinikum Essen, Essen, Deutschland. markus.schmidt@medizin.uni-essen.de
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: R
authors.initials: R
authors.lastname: Kimmig
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003110:Colonic Neoplasms / Q000517:prevention & control; D003704:Dementia / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D009652:Norpregnenes / Q000008:administration & dosage / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000139:chemically induced; D011322:Primary Prevention; D011372:Progestins / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced; D013923:Thromboembolism / Q000139:chemically induced; D013997:Time Factors
chemical_list: D020847:Estrogen Receptor Modulators; D004967:Estrogens; D009652:Norpregnenes; D011372:Progestins; C027385:tibolone